R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)

Lymphoma Clinical Trial

Official title:

Open-labeled, Multicenter Phase II Study of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients With Non-conjunctival Ocular Adnexal MALT Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01427114
• Other study ID #: KUH1010258
• Status: Completed
• Phase: Phase 2
• Start date: July 1, 2011
• Est. completion date: January 1, 2021

Study information

• Verified date: May 2021
• Source: Konkuk University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine how efficient the combination of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) is in the treatment of stage I or II non-conjunctival ocular adnexal MALT lymphoma (OAML).

Description:

The treatment of stage I or II OAML is mainly composed of radiotherapy because chemotherapy including cyclophosphamide, vincristine, and prednisolone (CVP) did not show the acceptable response rate compared with radiotherapy. However, radiotherapy for this disease can cause many complications of eyes. This clinical trial was designed to examine the efficacy of R-CVP combination therapy as a first-line treatment for stage I or II non-conjunctival OAML aiming to avoid radiation hazard and increase the efficacy of CVP chemotherapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: January 1, 2021
• Est. primary completion date: August 1, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed OAML

• Non-conjunctival or bilateral conjunctival (TNM-based, above T1N0M0 or bT1N0M0), Ann Arbor stage I and II OAML

• Previously untreated

• Age =18 years

• Performance status: ECOG 0-2

• Adequate hematological function: hemoglobin =9 g/dL,, absolute neutrophil count (ANC) =1,500/µL, and platelet count =100,000/µL, unless abnormalities are due to bone marrow involvement by the lymphoma

• Adequate liver function tests:

i. Transaminase (AST/ALT) <3 times the upper normal value ii. Bilirubin <2 times the upper normal value

• Adequate renal function:serum creatinine level <2 mg/dL (177 µmol/L)

• Life expectancy = 6 months

• A negative serum or urine pregnancy test before treatment must be available for both premenopausal women and for women who have <2 years after the onset of menopause.

• Informed consent

Exclusion Criteria:

• NHL subtypes other than OAML

• Primary conjunctival OAML, unilateral involved (T1N0M0)

• Ann Arbor stage III or IV

• CNS involvement by the lymphoma or any evidence of spinal cord compression. Brain CT/MRI is only mandatory (within 4 weeks) with clinical suspicion of CNS involvement by the lymphoma

• Pregnant or lactating women, women of child-bearing potential not using adequate contraception

• Inadequate liver function tests:

i. Transaminase (AST/ALT) =3 times the upper normal value or ii. Bilirubin =2 times the upper normal value

• Inadequate renal function:

i. serum creatinine level <2 mg/dL (177 µmol/L)

• Other serious illness or medical conditions i. Unstable cardiac disease despite treatment; myocardial infarction within 6 months prior to study entry ii. History of significant neurological or psychiatric disorders including dementia or seizures

• Active uncontrolled infection (HIV, hepatitis B, Hepatitis C, active Tuberculosis, active bacterial, or active fungal infection)

• Any other malignancies within the past 5 years except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri

• Known hypersensitivity to any of the study drugs or its ingredients (i.e., hypersensitivity to Polysorbate 20, CHO cell products, or recombinant human antibodies)

• Concomitant administration of any other experimental drug under investigation or concomitant chemotherapy, hormonal therapy, or immunotherapy

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell, Marginal Zone

Intervention

Drug:
• rituximab, cyclophosphamide, vincristine, and prednisolone
6 cycles of R-CVP followed by 2 cycles of rituximab

Locations

Country	Name	City	State
Korea, Republic of	KonKuk University Medical Center	Seoul
Korea, Republic of	Seoul St. Mary's Hospital	Seoul

Sponsors (2)

Lead Sponsor	Collaborator
Konkuk University Medical Center	Seoul St. Mary's Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	complete response rate	CR rate	3 years
Secondary	Progression free survival	Progression free survival	5 years
Secondary	Overall survival	Overall survival	5 years
Secondary	Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Number of Participants with Adverse Events as a Measure of Safety and Tolerability	5 years